In May 2026, the European Parliament and Council reached provisional agreement on the Critical Medicines Act. Most of the coverage treated it as a supply chain story. It is also a business development story, and the companies that read it that way will be in a materially better position by 2027.
The List Is Already There
The Union List of Critical Medicines identifies over 200 active substances where the EU has formally determined that supply continuity is a priority concern. The list has been public since 2023. What the Act does is give it legislative teeth: member states will be required to monitor stock levels, report shortages, and for the first time, take coordinated action when supply falls below defined thresholds.
Cancer drugs are already in active shortage. Methotrexate, fluorouracil, cisplatin, paclitaxel. All on the list. All in intermittent shortage across EU markets. These are not obscure molecules. They are the backbone of oncology treatment protocols in hospitals across Europe.
The capacity to manufacture them exists. Much of it is in China. The deals that would connect EU commercial infrastructure to that manufacturing capacity are not being made fast enough.
What Changes for BD Teams
The Act does not create a fast lane for China-sourced generics into EU markets. Regulatory pathway, CMC requirements, QP sign-off, GMP inspection status. None of that changes. What changes is the political and commercial environment in which you make the case for pursuing these deals.
For years, shortage-driven sourcing was treated as a defensive, reactive problem. Something procurement handled when a tender came in with no viable bidder. The Act repositions it as a strategic priority. That matters internally. It is easier to get a new in-licensing programme approved when the board can see that EU policy explicitly identifies the category as a resilience gap.
It also matters commercially. Chinese manufacturers who hold NMPA approval on shortage-listed products are, in some cases, already aware that their assets appear on EU shortage lists. The ones who have thought about what that means for licensing negotiations have a different conversation to offer than the ones who have not.
The Timing Problem Hasn’t Gone Away
The Act creates urgency at the policy level. It does not speed up the underlying work.
Getting a China-manufactured product to EU market still requires establishing which regulatory pathway applies, conducting a manufacturing gap analysis against EU GMP expectations, and confirming API supplier CEP status or planning the 18 to 24 months it takes to get one. None of that has shortened.
What has shortened is the window in which to be first. The companies that begin qualification work on shortage-listed assets now will have a meaningful advantage over those who wait for implementation measures to be finalised before deciding to act. By that point, the obvious assets will have been identified by everyone.
What to Actually Do
If your company has commercial infrastructure in a therapeutic area where shortage-listed products are concentrated, the immediate step is not a legislative read-through. It is a mapping exercise: which products on the Union List fall within your commercial footprint, and what does the manufacturing landscape look like for each?
For a mid-sized EU generics or specialty pharma company, this is a two to four week exercise. It will not tell you which specific Chinese partner to approach. That requires on-the-ground qualification. But it will tell you whether there is a category-level opportunity worth pursuing, and what the regulatory runway looks like before a deal could translate to supply.
That is the brief worth having before the search begins.
SEQOVA’s Position
SEQOVA tracks shortage list opportunities as part of its standard asset identification process. For EU companies with commercial infrastructure and an appetite for complex generics, shortage-listed products represent some of the clearest intersections of policy mandate and commercial logic that the EU pharma market has seen in a decade. If you are starting that mapping exercise and want a second perspective on where the viable manufacturing options sit, that is the conversation we have.